The Syllabus area of the myCourses course template is organized into the following sections:
Much of the information needed for the Course Information and Expectations section—particularly the all-important learning outcomes and assessment methods—should be taken directly from the official Course Outline Form for your assigned course(s). Your department chair or program head can provide you with the form(s) and guidance on what is and is not modifiable in the transition to a course syllabus. If you are designing a new course, however, you will need to successfully complete the RIT course proposal process.
Before completing the Course Policies section, we encourage you to first consult our companion webpage, RIT Policies for Your Syllabus. The External Resources section (below) provides helpful information, advice, and examples for developing the remaining sections of your syllabus.
Regardless of where you are in the syllabus-design process, you can always request one-on-one consultations with an Instructional Design Researcher and Consultant.
usatoday.com cannot provide a good user experience to your browser. To use this site and continue to benefit from our journalism and site features, please upgrade to the latest version of Chrome, Edge, Firefox or Safari.
Summary This latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis (IBM) - Drugs In Development, 2022, provides an overview of the Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline landscape.
New York, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Inclusion Body Myositis (IBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" - https://www.reportlinker.com/p06319569/?utm_source=GNW
Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as the blood vessels that supply the muscles. IBM symptoms include progressive weakness of the muscles of the wrists and fingers, the muscles of the front of the thigh, and the muscles that lift the front of the foot.
Pharmaceutical and Healthcare latest pipeline guide Inclusion Body Myositis (IBM) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Inclusion Body Myositis (IBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 3 and 2 respectively.
Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most exact developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Inclusion Body Myositis (IBM) (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Read the full report: https://www.reportlinker.com/p06319569/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
Oct. 6 (UPI) -- President Joe Biden spoke Tuesday in Poughkeepsie, N.Y., and touted IBM's announcement that it plans to invest $20 billion across the Hudson Valley on research and development initiatives over the next 10 years.
Biden hailed the investments and said that the supply chain crises during the COVID-19 pandemic have made Americans more aware of the issue. As a result, he has pushed for more semiconductor manufacturing to come back to the United States.
"As we saw during the pandemic, when factories that make these chips shut down around the world, the global economy literally comes to a screeching halt," Biden said. "More Americans have learned the phrase 'supply chain.' Well, guess what? The supply chain is going to start here and end here, in the United States."
The IBM announcement comes after Micron said Tuesday it will build a $500 million semiconductor fabrication facility in New York.
The announcements highlight the recently signed Creating Helpful Incentives to Produce Semiconductors and Science Act, also known as CHIPS, that Biden signed into law in August, which provided financial incentives for companies to build semiconductors critical to many components today in the United States.
"IBM is deeply honored to host President Biden at our Poughkeepsie site today and we look forward to highlighting our commitments to the innovations that advance America's economy," Arvind Krishna, chairman and CEO of IBM, said in a statement.
"As we tackle large-scale technological challenges in climate, energy, transportation and more, we must continue to invest in innovation and discovery because advanced technologies are key to solving these problems and driving economic prosperity, including better jobs, for millions of Americans."
IBM said its Poughkeepsie site has manufactured armaments during World War II and developed the latest generation of mainframe computers. It also builds state-of-the-art mainframe computers that power the global economy.
"The site also is home to IBM's first Quantum Computation Center -- where a large number of real quantum computers run in the cloud," IBM said in a statement. "IBM's vision is for Poughkeepsie to become a global hub of the company's quantum computing development, just as it is today for mainframes."
The Poughkeepsie plant is home to about 3,000 workers while IBM hires more than 7,500 employees throughout the region.
The investment provides a much needed victory for the President, who is dealing with the beginnings of a possible downturn in the economy. Job openings in August fell to their lowest levels since August 2020 and the federal reserve has promised to keep tightening the economy until inflation is under control.
The federal government through the Ministry of Communications and Digital Economy, has signed a memorandum of understanding (MoU) with Tech giant, International Business Machines (IBM) West Africa.
The deal is for partnership and collaboration in the area of digital skills development in Nigeria.
The Minister of Communications and Digital Economy, Dr. Isa Pantami, who signed on behalf of the federal government, said the partnership would deliver impetus to the digital, innovation and entrepreneurship skills of the economic development plan of President Muhammadu Buhari.
He described the partnership as a quantum leap in the digital economy strategy of the ministry.
The MoU, which was signed in Abuja recently, is scheduled to take off in February 2020.
The MoU provides a platform to empower Nigerian youths with digital literacy skills, enable innovation, design and development of indigenous solutions, self -sufficiency and make Nigeria a hub for critical skills for Africa and the world at large.
Under the partnership, and in line with the Digital Literacy initiative and drive of the Minister, IBM would through its Digital Nation Africa Initiative, provide free training to Nigerians for a period of 12 to 16 weeks, in diverse areas of Information Technology (IT).
The MoU seeks to create awareness and support in the development and use of digital tools and applications to Improve the delivery of government services; create a pool of Nigerians with digital skills validated by globally recognised certifications; bridge the gap between the academia and the industry through sensitisation on digital tools and skills; and lower the access barrier to digital tools for the citizens.
Addressing IBM representatives led by the Country General Manager, Pantami expressed satisfaction at the organisation’s response to the digital economy policy by, sufficiently keying in, to bridge the divide between the academia and the industry, education and entrepreneurship.
Pantami noted that, “to achieve a digital economy, digital skills are central, and this has been adequately captured in the second pillar of the Digital Economy Strategy Policy Document as approved and launched by the President on the 28th of November 2019.”
The minister further disclosed that the importance of broadband in the implementation of a digital economy is the life line to its success and this again has been reflected in the seventh pillar of the strategy document.
“The importance of broadband penetration in achieving a digital economy has given rise to the National Broadband Committee to ensure that we thoroughly address the impediments to broadband penetration and achieving a Digital Economy,” Pantami said.
The minister urged institutions of learning to deliver priority to skills, especially digital skills over paper qualifications.
According to him, “Digital skills are more relevant in today’s world of emerging technologies, therefore we must encourage innovation and drive digital literacy and skills among the populace.”
In his remarks, the Country General Manager at IBM, Mr. Dipo Faulkner, said: “IBM works with governments and key Ministries to address the societal impact of digital technology, leveraging our investment in education with platforms such as IBM Digital Nation Africa. This new collaboration furthers our aims of scaling digital job skills across Africa.”
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
23 September 2022
by Jon Grevatt
LIG Nex1's low-altitude missile defence system, a model of which is shown above, has a range of 7 km. (Janes/Dae Young Kim)
South Korea's LIG Nex1 has disclosed plans to supply its low-altitude missile defence (LAMD) system to the Republic of Korea (RoK) Armed Forces by the end of the decade.
The company started development of the system earlier this year, and told Janes at the DX Korea 2022 exhibition in Goyang that the LAMD will undergo seven more years of work before it is ready for deployment.
“We have planned two years of engineering development, one year to prepare for full-scale development, and four more years of full-scale development,” said an LIG Nex1 official.
The company is developing the system in collaboration with the Agency for Defense Development (ADD).
The LAMD, which is based on the Haegung Korean Surface-to-Air Anti-Missile (K-SAAM) system developed for the Republic of Korea Navy (RoKN), underwent its first test in April. This featured a test-firing from the ADD's launch facility in Anheung.
Janes has earlier reported that the LAMD missile is fitted with an active radar seeker for terminal guidance. The missile is 165 mm in diameter and can intercept targets up to 7 km away and 5 km in altitude.
The launcher demonstrated at DX Korea 2022 had 16 containers in a 4×4 arrangement. It is expected that the launcher would also be mounted on a semitrailer.
South Korea's LIG Nex1 has disclosed plans to supply its low-altitude missile defence (LAMD) system ...